Effects of morphine, fentanyl and tramadol on human immune response

Abstract

Morphine has been reported to suppress human immune response. We aimed to observe the effects of morphine, fentanyl and tramadol on NF-κB and IL-2 from both laboratory and clinical perspective. Jurkat cells were incubated with ten times clinically relevant concentrations of morphine, fentanyl and tramadol before being stimulated with PMA. NF-κB binding activity and IL-2 levels were measured. In the clinical study, 150 consenting patients were randomized into 3 groups according to the analgesics used in them, namely, group morphine (M), group fentanyl (F) and group tramadol (T). IL-2 was measured preoperatively and 1, 3 and 24 h after operation. Consequently, NF-κB activation was suppressed by morphine and fentanyl but not by tramadol. IL-2 was significantly decreased by morphine and fentanyl but not by tramadol in vitro. In the PCA patients, IL-2 was decreased in group M and increased in group F postoperatively. Whereas in group T, IL-2 was unchanged 1 h after operation but was significantly elevated 3 and 24 h after operation. Our results showed that the inhibition of morphine on IL-2 was most probably related to its suppression on NF-κB. Fentanyl had different effects on human immune response in vitro and in vivo. Tramadol may have immune enhancing effect.

Keywords

morphine / fentanyl / tramadol / NF-κB / IL-2

References

[1] MalikA. A., RadhakrishnanN., ReddyK., et al.. Morphine-induced macrophage apoptosis modulates migration of macrophages: use of in vitro model of urinary tract infection. J Endourol, 2002, 16(8): 605-610

[2] Gaveriaux-RuffC., MatthesH. W., PelusoJ., et al.. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci U S A, 1998, 95(11): 6326-6330

[3] PahlH. L.. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 1999, 18(49): 6853-6866

[4] LoopT., LiuZ., HumarM., et al.. Thiopental inhibits the activation of nuclear factor kappaB. Anesthesiology, 2002, 96(5): 1202-1213

[5] RoyS., CainK. J., ChapinR. B., et al.. Morphine modulates NF kappa B activation in macrophages. Biochem Biophys Res Commun, 1998, 245(2): 392-6

[6] WeltersI. D., MenzebachA., GoumonY., et al.. Morphine inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology, 2000, 92(6): 1677-84

[7] GhoshS.. Regulation of inducible gene expression by the transcription factor NF-kappaB. Immunol Res, 1999, 19(2–3): 183-9

[8] YamamotoY., GaynorR. B.. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest, 2001, 107(2): 135-42

[9] HouseR. V., ThomasP. T., BhargavaH. N.. In vitro evaluation of fentanyl and meperidine for immunomodulatory activity. Immunol Lett, 1995, 46(1–2): 117-24

[10] YeagerM. P., ProcopioM. A., DeLeoJ. A., et al.. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesth Analg, 2002, 94(1): 94-9

[11] MagriniM., RivoltaG., BolisC., et al.. Analgesic activity of tramadol and pentazocine in postoperative pain. Int J Clin Pharmacol Res., 1998, 18(2): 87-92

[12] SacerdoteP., BianchiM., ManfrediB., et al.. Efects of tramadol on immune responses and nociceptive thresholds in mice. Pain, 1997, 72: 325-330

[13] SacerdoteP., BianchiM., GaspaniL., et al.. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg, 2000, 90(6): 1411-4

[14] LivnatS., FeltenS. Y., CarlsonS. L., et al.. Involvement of peripheral and central catecholamine systems in neural-immune interactions. J Neuroimmunol, 1985, 10(1): 5-30

[15] MaddenK. S., MoynihanJ. A., BrennerG. J., et al.. Sympathetic nervous system modulation of the immune system. III. Alterations in T and B cell proliferation and differentiation in vitro following chemical sympathectomy. J Neuroimmunol, 1994, 49(1–2): 77-87

[16] TaubD. D., EisensteinT. K., GellerE. B., et al.. Immunomodulatory activity of mu-and kappa-selective opioid agonists. Proc Natl Acad Sci U S A, 1991, 88(2): 360-4